MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab

Mensà, Emanuela; Recchioni, Rina; Marcheselli, Fiorella; Giuliodori, Katia; Consales, Veronica; Molinelli, Elisa; Prattichizzo, Francesco; Rippo, Maria Rita; Campanati, Anna; Procopio, Antonio Domenico; Olivieri, Fabiola; Offidani, Annamaria

doi:10.1111/bjd.16659

Cited by 21 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding miRNAs levels as diagnostic biomarkers of dementia, our study showed a significant increase of CSF miR-222 levels in VD patients, suggesting a potential role in supporting the diagnosis of vascular dementia. MiR-222 was previously defined as an anti-angiogenic miR, upregulated in vascular walls with neointimal lesion formation [34–36]. Notably, circulating miR-222 levels were recently proposed as promising and independent biomarkers for the risk of acute ischemic stroke [37].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of new and classic CSF biomarkers in age-related dementias

Marchegiani

Matacchione

Ramini

et al. 2019

Aging

View full text Add to dashboard Cite

The identification of diagnostic-prognostic biomarkers of dementia has become a global priority due to the prevalence of neurodegenerative diseases in aging populations. The objective of this study was to assess the diagnostic performance of cerebrospinal fluid (CSF) biomarkers across patients affected by either Alzheimer’s disease (AD), tauopathies other than AD (TP), or vascular dementia (VD), and cognitively normal subjects (CNS). One hundred fifty-three patients were recruited and tested for classical AD CSF biomarkers- Amyloid-ß42 and tau proteins - and novel candidate biomarkers - neurofilament (NF-) light and microRNA (miR) -21, -125b, -146a, and -222. All dementia patients had significantly higher concentrations of NF-light compared to CNS, with the TP group displaying the highest NF-light values. A significant inverse correlation was also observed between NF-light and cognitive impairment. Of the four miRNAs analyzed, miR-222 levels were significantly increased in VD patients compared to both CNS and AD. In addition, while NF-light showed a better diagnostic performance than miR-222 and classical AD biomarkers in differentiating TP and VD from CNS, classical AD biomarkers revealed higher performance in discriminating AD from non-AD disorders. Overall, our results suggest that CSF NF-light and miR-222 are promising biomarkers that may help to diagnose non-AD disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of new and classic CSF biomarkers in age-related dementias

Marchegiani

Matacchione

Ramini

et al. 2019

Aging

View full text Add to dashboard Cite

show abstract

“…Additionally, studies have shown that miR-146a has a connection with TNF-α in gastric diseases and psoriasis patients 31 , 32 . miR-146a can increase the secretion of TNF-α, which is confirmed by experiments.…”

Section: Introductionmentioning

confidence: 55%

Nuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy

Liu

Shao

Zhou

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Nuclear factor κB (NF-κB) acts as a nuclear factor that is composed of five main subunits. It is a pluripotent and crucial dimer transcription factor that has a close relationship with many serious illnesses, especially its influences on cell proliferation, inflammation, and cancer initiation and progression. NF-κB acts as part of the signaling pathway and determines its effect on the expression of several other genes, such as epidermal growth factor receptor (EGFR), p53, signal transducer and activator of transcription 3 (STAT3), and non-coding RNA (ncRNA). Continuous activation of the NF-κB signaling pathway has been seen in many cancer types. While the NF-κB signaling pathway is tightly regulated in physiological settings, quite frequently it is constitutively activated in cancer, and the molecular biology mechanism underlying the deregulated activation of NF-κB signaling remains unclear. In this review, we discuss the regulatory role and possible clinical significance of ncRNA (microRNA [miRNA] and long non-coding RNA [lncRNA]) in NF-κB signaling in cancer, including in the conversion of inflammation to carcinogenesis. Non-coding RNA plays an essential and complex role in the NF-κB signaling pathway. NF-κB activation can also induce the ncRNA status. Targeting NF-κB signaling by ncRNA is becoming a promising strategy of drug development and cancer treatment.

show abstract

“…However, we did not detect significant differences in miR-31 levels between lesional skin and residual lesions. The expression of miR-142-3p and miR-146a did not decrease either after treatment, although it has been described that the circulating levels of these miRNA are downregulated in etanercept and adalimumab responders patients, respectively [24,25]. However, the persistence of miR-146a levels in psoriasis patients after biological treatment has been also been reported [21].…”

Section: Discussionmentioning

confidence: 95%

Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement

Chicharro

Rodríguez‐Jiménez

Llamas‐Velasco

et al. 2020

Cells

View full text Add to dashboard Cite

miRNAs have been associated with psoriasis since just over a decade. However, we are far from a complete understanding of their role during the development of this disease. Our objective was to characterize the cutaneous expression of miRNAs not previously described in psoriasis, the changes induced following the treatment with biologicals and their association with disease improvement. Next generation sequencing was performed from five skin samples from psoriasis patients (lesional and non-lesional skin) and five controls, and from this cohort, 12 microRNAs were selected to be analyzed in skin samples from 44 patients with plaque psoriasis. In 15 patients, an additional sample was obtained after three months of biological treatment. MiR-9-5p, miR-133a-3p and miR-375 were downregulated in the lesional skin of psoriasis patients. After treatment, expression of miR-133a-3p, miR-375, miR-378a and miR-135b in residual lesions returned towards the levels observed in non-lesional skin. The decrease in miR-135b levels after treatment with biologics was associated with both the improvement of patients evaluated through Psoriasis Area and Severity Index score and the decrease in local inflammatory response. Moreover, basal expression of miR-135b along with age was associated with the improvement of psoriasis, suggesting its possible usefulness as a prognostic biomarker.

show abstract

MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab

Cited by 21 publications

References 8 publications

Diagnostic performance of new and classic CSF biomarkers in age-related dementias

Diagnostic performance of new and classic CSF biomarkers in age-related dementias

Nuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy

Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement

Contact Info

Product

Resources

About